A study in the Journal of the American Academy of Child and Adolescent Psychiatry (JAACAP), published by Elsevier, found that pharmacological treatment of attention-deficit/hyperactivity disorder
UVA Health researchers have developed a powerful new risk assessment tool for predicting outcomes in heart failure patients. The researchers have made the tool publicly
Using human cells in laboratory rats, Michigan Medicine researchers have developed a functional model of thoracic aortic aneurysm, creating opportunities for more effective understanding of
Asking young adults to advise their younger selves could have a positive impact on their self-esteem, resilience and mental health, according to a new study
Artificial intelligence (AI) computer programs that process MRI results show differences in how the brains of men and women are organized at a cellular level,
A new editorial published this May in the British Journal of Sports Medicine by experts from Spaulding Rehabilitation, Boston University, Mayo Clinic, and the Concussion
People with a common heart condition were able to use significantly more oxygen while exercising after taking an investigational drug in an international clinical trial,
TORONTO, May 14, 2024–(BUSINESS WIRE)–Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company“), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new
The opportunistic bacterial pathogen Pseudomonas aeruginosa is dangerous due to its resistance to multiple antibiotics.
VANCOUVER, British Columbia, May 14, 2024 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada-licensed GMP psychedelics pharmaceutical